The Training Program in Pharmacological Sciences at Stony Brook University trains Ph.D. students in the broad area of cell and molecular Pharmacology for careers in academia, government and industry. The Program is based in the Department of Pharmacological Sciences in the School of Medicine at Stony Brook University, but is interdisciplinary and interdepartmental in nature. It includes 38 potential mentors, 24 of whom are from other University Departments or the nearby Cold Spring Harbor Laboratory. Students take courses in Physiology, as well as basic principles and systems Pharmacology. The Training Program provides training in quantitative research skills, scientific communication and writing, and supports multiple career development activities, training in rigor and reproducibility and in the responsible conduct of research. The interdisciplinary training environment includes active seminar series and participation in research symposia and workshops. Training also involves teaching in courses offered to undergraduate majors in pharmacology. First year students participate in three laboratory rotations to prepare them to undertake dissertation research in any of the laboratories of the Training Program Faculty. The Training Program has trained nearly 150 Ph.D. students in its 39-year history, and has 25 current trainees. The presence of six underrepresented minority trainees and three students with disabilities currently in the program attests to a successful effort to recruit minority applicants.
Program narrative The Training Program in Pharmacological Sciences provides PhD students with a solid background in the discipline of Pharmacology by bringing together training faculty from different research fields involved in the discovery, development and use of therapeutic compounds, exposing students to relevant clinical problems, emphasizing translational research, and providing opportunities to the students to present their research in national and international meetings. The program offers courses both in basic principles and systems Pharmacology, provides training in quantitative research skills, scientific communication and writing, and supports career development activities to ensure the success of students in subsequent research-intensive or research-related careers. The training grant supports students early during their training (1st and 2nd year), aids in the recruitment and retention of diverse students and upholds a culture of responsible conduct in research, rigor and reproducibility in the scientific enterprise. The outcomes of the program are outstanding. Our alumni are represented in the entire spectrum of the research enterprise, leading research groups in academia and industry, defining patent law or shaping future research policy.
|Miyauchi, Jeremy Tetsuo; Tsirka, Stella E (2018) Advances in immunotherapeutic research for glioma therapy. J Neurol 265:741-756|
|Amin, Johansen B; Leng, Xiaoling; Gochman, Aaron et al. (2018) A conserved glycine harboring disease-associated mutations permits NMDA receptor slow deactivation and high Ca2+ permeability. Nat Commun 9:3748|
|Amin, Johansen B; Wollmuth, Lonnie P (2018) A Swiss army knife for targeting receptors. Elife 7:|
|Kirschen, Gregory W; Kéry, Rachel; Liu, Hanxiao et al. (2018) Genetic dissection of the neuro-glio-vascular machinery in the adult brain. Mol Brain 11:2|
|Nissen, Jillian C; Thompson, Kaitlyn K; West, Brian L et al. (2018) Csf1R inhibition attenuates experimental autoimmune encephalomyelitis and promotes recovery. Exp Neurol 307:24-36|
|Caponegro, Michael D; Moffitt, Richard A; Tsirka, Stella E (2018) Expression of neuropilin-1 is linked to glioma associated microglia and macrophages and correlates with unfavorable prognosis in high grade gliomas. Oncotarget 9:35655-35665|
|Miyauchi, Jeremy Tetsuo; Caponegro, Michael D; Chen, Danling et al. (2018) Deletion of Neuropilin 1 from Microglia or Bone Marrow-Derived Macrophages Slows Glioma Progression. Cancer Res 78:685-694|
|Thompson, Kaitlyn K; Nissen, Jillian C; Pretory, Amanda et al. (2018) Tuftsin Combines With Remyelinating Therapy and Improves Outcomes in Models of CNS Demyelinating Disease. Front Immunol 9:2784|
|Pulkoski-Gross, Michael J; Uys, Joachim D; Orr-Gandy, K Alexa et al. (2017) Novel sphingosine kinase-1 inhibitor, LCL351, reduces immune responses in murine DSS-induced colitis. Prostaglandins Other Lipid Mediat 130:47-56|
|Kirschen, Gregory W; Shen, Jia; Tian, Mu et al. (2017) Active Dentate Granule Cells Encode Experience to Promote the Addition of Adult-Born Hippocampal Neurons. J Neurosci 37:4661-4678|
Showing the most recent 10 out of 78 publications